A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate efficacy and safety of XP12B for the treatment of menorrhagia.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate efficacy and safety of XP12B for the treatment of menorrhagia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2010

At a glance

  • Drugs Tranexamic acid (Primary)
  • Indications Menorrhagia
  • Focus Registrational; Therapeutic Use
  • Sponsors Xanodyne Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2010 Ferring Pharmaceuticals added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 19 May 2010 Efficacy and QoL results presented at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 19 May 2010 Results data were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting, accoring to a Ferring Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top